Department of Chemistry, Lomonosov Moscow State University, Leninskie Gory 1-3, 119991 Moscow, Russia.
Gause Institute of New Antibiotics, B. Pirogovskaya 11, 119021 Moscow, Russia.
Molecules. 2022 May 31;27(11):3546. doi: 10.3390/molecules27113546.
The application of non-planar scaffolds in drug design allows for the enlargement of the chemical space, and for the construction of molecules that have more effective target-ligand interactions or are less prone to the development of resistance. Among the works of the last decade, a literature search revealed spirothiazamenthane, which has served as a lead in the development of derivatives active against resistant viral strains. In this work, we studied the novel molecular scaffold, which resembles spirothiazamenthane, but combines isoxazoline as a heterocycle and cyclooctane ring as a hydrophobic part of the structure. The synthesis of new 3-nitro- and 3-aminoisoxazolines containing spiro-fused or 1,2-annelated cyclooctane fragments was achieved by employing 1,3-dipolar cycloaddition of 3-nitro-4,5-dihydroisoxazol-4-ol 2-oxide or tetranitromethane-derived alkyl nitronates with non-activated alkenes. A series of spiro-sulfonamides was obtained by the reaction of 3-aminoisoxazoline containing a spiro-fused cyclooctane residue with sulfonyl chlorides. Preliminary screening of the compounds for antiviral, antibacterial, antifungal and antiproliferative properties in vitro revealed 1-oxa-2-azaspiro[4.7]dodec-2-en-3-amine and 3a,4,5,6,7,8,9,9a-octahydrocycloocta[d]isoxazol-3-amine with activity against the influenza A/Puerto Rico/8/34 (H1N1) virus in the submicromolar range, and high values of selectivity index. Further study of the mechanism of the antiviral action of these compounds, and the synthesis of their analogues, is likely to identify new agents against resistant viral strains.
非平面支架在药物设计中的应用允许扩大化学空间,并构建具有更有效靶标-配体相互作用或不易产生耐药性的分子。在过去十年的工作中,文献检索发现了螺噻嗪烷,它已被用作开发针对耐药病毒株的衍生物的先导化合物。在这项工作中,我们研究了一种新型分子支架,它类似于螺噻嗪烷,但将异噁唑啉作为杂环,并将环辛烷环作为结构的疏水区。通过 3-硝基-4,5-二氢异噁唑-4-醇 2-氧化物或四硝基甲烷衍生的烷基硝酮与非活化烯烃的 1,3-偶极环加成反应,合成了含有螺稠合或 1,2-并环化的环辛烷片段的新型 3-硝基-和 3-氨基异噁唑啉。通过含有螺稠合环辛烷残基的 3-氨基异噁唑啉与磺酰氯的反应,得到了一系列螺磺酰胺。对这些化合物进行了体外抗病毒、抗菌、抗真菌和抗增殖活性的初步筛选,发现 1-氧杂-2-氮杂螺[4.7]十二-2-烯-3-胺和 3a,4,5,6,7,8,9,9a-八氢环辛[d]异噁唑-3-胺对甲型流感病毒/波多黎各/8/34(H1N1)具有亚微摩尔范围内的活性,并且具有较高的选择性指数。进一步研究这些化合物的抗病毒作用机制以及它们的类似物的合成,可能会发现针对耐药病毒株的新药物。